BBIO vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 14, 2026

BBIO

49.4
AI Score
VS
BBIO Wins

MRNA

44.2
AI Score

Investment Advisor Scores

BBIO

49score
Recommendation
HOLD

MRNA

44score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BBIO MRNA Winner
Revenue 438.19M 534.00M MRNA
Net Income -322.45M -2.13B BBIO
Net Margin -73.6% -397.9% BBIO
Operating Income -213.03M -2.20B BBIO
ROE 12.8% -31.4% BBIO
ROA -26.5% -19.4% MRNA
Total Assets 1.22B 10.96B MRNA
Cash 677.91M 1.72B MRNA
Debt/Equity -1.05 0.09 BBIO
Current Ratio 1.23 2.29 MRNA
Free Cash Flow -268.89M -1.25B BBIO

Relative Price Performance (Last 90 Days)

BBIO 1M: -1.7% · 3M: +16.0% MRNA 1M: +154.5% · 3M: +207.1%

Current Technical Phase

BBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.9 · Price: $81.50

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (17.2% over 20 days), RSI 72

RSI (14): 71.6 · Price: $145.13

Fundamentals Snapshot

Metric BBIO MRNA
Market Cap
Forward P/E 532.0 -29.8
Trailing P/E
Revenue (TTM)
Revenue Growth 1.2% 0.0%
Gross Margin 0.9% -0.7%
Operating Margin -0.4% -5.6%
EPS -3.52 -6.11
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BBIO is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.